Indication

Primary biliary cholangitis

Primary biliary cholangitis is a chronic autoimmune cholestatic liver disorder characterized by T-lymphocyte–mediated inflammation and gradual destruction of the small intrahepatic bile ducts. Read more about Primary biliary cholangitis

18 drugs 13 manufacturers

Advertisement

Drugs that treat it

Common Primary biliary cholangitis therapies.

Showing 1–9 of 18 drugs

URSODIOL

GALLSTONE SOLUBILIZING AGENTS·PRIMARY BILIARY CHOLANGITIS
GLENMARK PHARMA

URSODIOL

PRIMARY BILIARY CHOLANGITIS
WATSON LABS

URSODIOL

PRIMARY BILIARY CHOLANGITIS
ACTAVIS PHARMA,

URSODIOL

GALLSTONE SOLUBILIZING AGENTS·PRIMARY BILIARY CHOLANGITIS
PAR HEALTH USA,

URSODIOL

PRIMARY BILIARY CHOLANGITIS
GLOBAL PHARM
Filter & compare in the drug finder →Opens the drug finder with Primary biliary cholangitis preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Primary biliary cholangitis.

Primary biliary cholangitis is a chronic autoimmune cholestatic liver disorder characterized by T-lymphocyte–mediated inflammation and gradual destruction of the small intrahepatic bile ducts.

This progressive ductopenia impairs bile acid secretion, resulting in toxic intrahepatic cholestasis, chronic periportal inflammation, and downstream hepatic parenchymal damage.

The disease most commonly affects middle-aged women and is clinically characterized by elevated alkaline phosphatase, the presence of serum antimitochondrial antibodies, and presenting symptoms such as fatigue and pruritus.

Without intervention, sustained cholestasis and fibrogenesis can lead to advanced cirrhosis, portal hypertension, and end-stage liver failure.

Personalize your experience

Follow Primary biliary cholangitis and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it